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Objective: Chagas disease constitutes a
major public health problem in Latin Amer-
ica. Correctly designed pharmacokinetic,
safety, and bioequivalence studies are de-
sirable in order to fill the knowledge gaps
that presently exist on available drugs. It is
necessary to develop accurate, simple, re-
producible, and sensitive high-performance
liquid chromatography (HPLC)/UV methods
for the quantization of benznidazole (BNZ)
in human plasma and urine for clinical ap-
plications, specially in pediatric patients.
Methods: Quantization of BNZ in hu-
man plasma involved freeze-drying and
re-suspension in organic solvent fol-
lowed by reverse phase HPLC with
UV detection. Analysis of BNZ in urine
involved liquid/liquid extraction followed by
reverse phase HPLC with UV detection.
Results: Limits of quantization (LOQ) were
0.32 μg/ml for plasma and 5.2 μg/ml
for urine. No metabolite interferences were
showed in both methods. Conclusion: The
LOQ of methods seems appropriate in
pediatric clinical contexts. Both proce-
dures were applied with good results, to
the quantization of BNZ in plasma and
urine of patients treated for Chagas dis-
ease. J. Clin. Lab. Anal. 27:384–390,
2013. C° 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Chagas disease, a protozoan infection caused by the
kitenoplastid Trypanosoma cruzi, constitutes a major
public health problem in Latin America. According to
current data, there are over seven million infected peo-
ple in the Americas (1) with an incidence of more than
40,000 new cases per year (2). Also, Chagas disease has
expanded to nonendemic regions such as North America
and Europe countries via immigration of infected indi-
viduals (3) and has been rising in the ranking of inter-
national health priorities due to the growing migration
flows from endemic to nonendemic areas (4). Most infec-
tions take place in children,mostly by vector or congenital
transmission (5).
Correctly designed pharmacokinetic, safety, and bioe-
quivalence studies are desirable in order to fill the know-
ledge gaps that presently exist on available drugs. In this
sense, it would be very helpful to establish the therapeutic
range of benznidazole (BNZ) in order to optimize dosage,
and to validate new pharmaceutical formulations for
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patients with Chagas disease in the acute phase, parti-
cularly children.
The aim of this work was to develop and validate fast,
accurate, precise, reproducible, and specific methods to
quantify BNZ in human plasma and urine, for further
application in clinical research, safety and regulatory pur-
poses, and for routine clinical use.
EXPERIMENTAL
Materials and Reagents
Trichloroacetic acid (TCA) and dichloro methane
(DCM) were purchased from Biopack (Buenos Aires, Ar-
gentina). Dimethyl sulfoxide (DMSO), anhidrous sodium
sulfate, and sodium hydroxide were obtained from Ane-
dra (Buenos Aires, Argentina). Ethyl acetate was ob-
tained from Dorwil (Buenos Aires, Argentina). Glycine
was obtained from Parafarm (Buenos Aires, Argentina).
Hydrochloric acid was obtained from J.T. Baker (USA).
All these reagents were proanalysis grade. Chromato-
graphic grade demineralized water (<0.2 μsiemens) was
obtained in our laboratory with ionic interchange resins.
Sodium octanesulfonate (Tedia, USA) and acetonitrile
(J.T. Baker, USA) high-performance liquid chromatog-
raphy (HPLC)-grade drug were used. BNZ was ob-
tained fromHoffmann-La Roche Ltd. (Buenos Aires, Ar-
gentina). Radanil R° (BNZ 100 mg) was obtained from
Roche (Sa˜o Paulo, Brazil).
A Rolco 2036 centrifuge and a rotary evaporator Hei-
dolph Laborota 4010 equipped with a ROTAVAP valve
control equipment were used for the pretreatment pro-
cedures. A certified analytical balance 0.1 mg (Ohaus-
Pionner, USA) was used in weighing operations. All mi-
cropipettes were calibrated before use. All HPLC sol-
vents were degassed with a vacuumpump (Pascal, Buenos
Aires, Argentine). An ultrasonic homogenizer (FAETA,
Argentina) and a Genesis G12 (VIRTIS R°, New York,
NY) freeze-drier were also used.
Stock and Working Solutions
Stock control solution was prepared with 112.8 mg of
BNZ in 5 ml of DMSO to complete dissolution and then
accurately diluted to 25.00 ml in a calibrated volumetric
flask, with acetonitrile to obtain a 4.512 mg/ml stock
control solution. This stock control solution was stored
at 4◦C.Variable volumes of the stock control solutionwere
diluted in themobile phase toobtain the standardworking
solutions (SWS). Standard control curve was made in
a duplicated mode at 0.10, 0.50, 1.00, 5.00, 20.00, and
45.00 μg/ml with these SWS.
Three SWS at 0.50, 1.00, and 5.00 μg/ml were stored
for three months at 4◦C. After this time were measured in
plasma chromatographic conditions.
HPLC Instrumentation and Calculation
The instrumental analytic methods development was
performed with an LC system consisting of an HPLC
Merck-Hitachi LC-6200A and Merck-Hitachi UV/Vis
L-4250 detector (Japan). Separations were carried out at
room temperature using a C18 column 5 μm, 100 mm ×
4.6 mm I.D. Lichrospher-100 RP18 (Merck, USA). Sam-
ples were injected with a manual injector system with a 20
μl sample loop. Peak areas were integrated automatically
by Merck-Hitachi D-2500 Chromato-Integrator.
All the calculations concerning the quantitative analysis
were performed with an external standardization by the
measurement of peak areas of a sample specimen series.
Limits of detection (LOD) were established at 3.3 times
of intercept coefficient standard error/slope coefficient ra-
tio. Limits of quantization (LOQ) were established at nine
times of intercept coefficient standard error/slope coeffi-
cient ratio. Accuracy and precision of the assays were
calculated based on the analysis of three replicates for
each level of the standard curve. Total uncertainty was
calculated as the sum of accuracy and precision. Sensi-
tivity calculation was carried out as the product of total
uncertainty with LOQ.
Plasma Samples
Preparation of control plasma samples
Drug-free plasma (2.000 ml), as a control specimen,
was spiked with the appropriate volume of stock con-
trol solution to attain standards with different BNZ con-
centrations. Plasma samples specimens were spiked at
0.10, 0.50, 1.00, 5.00, 10.00, 15.00, and 20.00 μg/ml
(two minors concentrations duplicated), which were used
to make calibration curve. These standards were freeze-
dried and stored at 4◦C until analysis. The stability of
BNZ in lyophilized plasma (1.00 μg/ml) was studied at
six months after storage at −21◦C, through an HPLC
measure.
Patients’ plasma samples
Plasma samples were obtained from pediatric pa-
tients treated for Chagas infection with Radanil R°
(5–8 mg/kg/day) aged between 2 and 12. These sam-
ples came from patients in one of three groups: group
I (patients at beginning of treatment), group II (pa-
tients in advanced in the treatment—i.e., at steady
state), and group III (patients at the end of treatment).
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All plasma samples were freeze-dried, transported, and
stored at 4◦C until analysis. Some random dupli-
cated samples were stored for six months for stability
studies.
Pretreatment of plasma control specimens and pa-
tients’ samples
Two sample volumes (4.000 ml) of ethyl acetate were
added to the lyophilized plasma for drug extraction. The
mixture was manually shaken and deproteinization was
carried out with 200 μl (1/10 sample volume) of TCA
(30% p/v), vortexed for one minute, and sonicated for five
minutes. The mixture was then centrifuged at 8000 g for
10 min, the supernatant was placed into a round bottom
glass flask and rotoevaporated to dryness at 40◦C and
90–120 bar until the organic solvent was eliminated. The
residue was resuspended in 600μl of the chromatographic
mobile phase and injected into the HPLC system.
Chromatographic conditions for plasma analysis
HPLC analysis was performed by isocratic elution with
a flow rate of 1.0 ml/min. The mobile phase composition
was glycine buffer/acetonitrile (75:25 v/v). The glycine
buffer was an aqueous solution of glycine 0.20 M and
sodium octanesulfonate 5 mM at pH 2.5. Hydrochloric
acid 50% v/v for pH adjustment was used. All solvents
were filtered through a 0.45 μm nylon membrane and
degassed before use.
The maximum UV absorption of BNZ is at 313 nm
in this chromatographic mobile phase, so this wavelength
was chosen for the method. A value of 0.030 absorbance
units (a.u.) threshold was used. Triplicate injections were
made for each plasma control specimen to test repro-
ducibility of the detector response at each concentration
level. The peak area was plotted against the concentration
to obtain the calibration graph. Regression analysis was
used to calculate the calibration equation and correlation
coefficients.
Urine Samples
Preparation of urine control specimen
Drug-free human duplicated urine specimens of
2.500mlwere spikedwith the appropriate volume of stock
control solution to attain urine control specimens at 5.0,
10.0, 20.0, 30.0, and45μg/mlfinalBNZconcentrations in
a duplicate series. These controls were mixed and stored
at 4◦C until pretreatment. Three random controls were
stored for six months at –21◦C for stability studies.
Patients’ urine samples
Twenty-four hour urine samples were obtained from
Chagas disease pediatric patients and from healthy adult
volunteers who received Radanil R° at 5–8 mg/kg/day
dose.All urine sampleswere stored at –21◦Cuntil analysis.
Pretreatment of urine control specimens and samples
Human urine samples (2.500 ml) were deproteinizated
with 250 μl of an aqueous solution of TCA (30% v/v).
After shaking for one minute, 225 μl of an alkaline so-
lution of NaOH (10% w/v) was added to adjust to pH
7.00 ± 0.02. A 1.250 ml volume of DCM (1/2 sample
volume) and 200.0 mg of anhydrous sodium sulfate (near
saturation) were added, shaking the mixture for two mi-
nutes. The organic phase of two consecutive liquid/liquid
extraction procedures was recovered. Both fractions were
rotoevaporated to dryness at 50◦Cand 40–80 bar in round
bottom glass flasks. The residue was resuspended in 1.500
ml of the mobile phase and then injected into the chro-
matographic system.
Chromatographic conditions for urine analysis
HPLC analysis was performed by isocratic elution with
a flow rate of 1.0 ml/min. The mobile phase composition
was water/acetonitrile (80:20 v/v). All solvents were fil-
tered through a 0.45 μm nylon membrane and degassed
before use.
The maximum UV absorption of BNZ is at 313 nm
in this chromatographic solvent, so this wavelength was
chosen for the method. A value of 0.100 absorbance units
threshold was used. Triplicate injections were made for
each urine control specimen to test reproducibility of the
detector response at each concentration level. The peak
area was plotted against the concentration to obtain the
calibration graph. This graph was subjected to regression
analysis to calculate the calibration equation and correla-
tion coefficients.
RESULTS
No significant loss was observed in the BNZ concen-
tration in DMSO/acetonitrile solutions (0.50, 1.00, and
5.00 μg/ml) and in lyophilized plasma (1.00 μg/ml) af-
ter three and six months, respectively. In addition, analyte
showed no decomposition products in the chromatogram.
After several trials glycine buffer/acetonitrile (75:25
v/v) as the mobile phase was found to achieve maximum
separation and sensitivity for plasma analysis. A wave-
length of 313 nm was selected for UV detection. Flow
rates between 0.8 and 1.5 ml/min were tested. A flow rate
of 1.0 ml/min gave an optimal signal-to-noise ratio with
J. Clin. Lab. Anal.
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TABLE 1. Correlation Coefficients of Human Plasma Curve
R value 0.9975
Adjusted-R squared 0.9948
Residual sum of squares 7.04826 × 107
Observations N = 27
ANOVA FN–2 = 7903.91451 Prob > FN–2 = 0
Coefficients Standard error
Intercept (b) 547.33247 221.49793
Slope (m) 6564.92771 50.24426
a reasonable separation time. The retention time for BNZ
was 6.30minwith a 1.5% intradayCVand a 3.2% interday
CV. Total run time was eight minutes per sample.
Table 1 presents correlation coefficient, F factor of
ANOVA analysis, and values of the slope and intercept
with relative standard deviation (RSD) for BNZ in plasma
samples. Good linearity was obtained with r2 = 0.99484.
The LOD and LOQwere calculated to be 0.14 μg/ml and
0.32 μg/ml, respectively.
The linear range was verified with linearity of extended
calibration curves and was based on the expected con-
centrations in probe samples. The linear ranges were de-
terminate between LOD and 20.0 μg/ml. Recovery at
1.00 μg/ml level was 89%.
Table 3 summarizes accuracy and precision. Total un-
certainty was below 10%. Sensitivity was 0.04 μg/ml, be-
low to the LOD value. The residual-lag-plot, constructed
by plotting residual (i) against residual (i-1), shows a non-
random pattern in a lag-plot (Fig. 1A). This suggests that
the variance is not random and the total CV is the same
in all the concentration range.
Chromatographic parameters such as resolution, selec-
tivity, and peak asymmetry were satisfactory for BNZ
determination with this technique. Interestingly, a second
peak was observed in some plasma samples belonging
to patients who were in the advanced treatment (i.e., af-
ter taking BNZ for several days). This peak eluted one
minute before BNZ (about 5.50 minutes; Fig. 2), and was
not present in samples belonging to patients at the begin-
ning or at the end of the medical treatment.
In urine analysis, a mobile phase of water/acetonitrile
(80:20 v/v) was chosen to achieve maximum separation
and sensitivity. Same conditions to those used in plasma
analysis were used (wavelength, flow rates, and technical
specification of column). Retention times for BNZ were
5.30 min, with an 8.9% intraday CV. Total run time was
seven minutes per sample. Chromatographic parameters
such as resolution, selectivity, and peak asymmetry were
satisfactory for determinationofBNZwith this technique.
Table 2 presents correlation coefficient, F factor of
ANOVA analysis, and values of the slope and intercept
with RSD for BNZ in urine samples. Good linearity
was obtained with r2 = 0.98832. LOD and LOQ were
Fig. 1. Residual-lag-plot on human plasma curve (A) and on hu-
man urine curve (B). Both showing that the error term is sufficiently
independent.
1.70μg/ml and 5.20μg/ml, respectively. Detection range
was linear between LOD and 45.00 μg/ml. Recovery at
15.00 μg/ml level was 70%.
Table 3 shows the accuracy and precision of the urine
assay. Total uncertainty was below 10% and sensitivity
was 0.5 μg/ml, below the LOD value. Residual-lag-plot
analysis shows a nonrandom pattern (Fig. 1B) that sug-
gests nonrandom variance in all the concentration range.
Plasma samples obtained from 21 patients and urine of
2 patients were tested to evaluate the performance of the
chromatographic methods. Results are shown in Table 4.
DISCUSSION
Only two drugs are currently available for the treatment
of Chagas disease, nifurtimox and BNZ, both with simi-
lar effectiveness (5, 6). Currently BNZ is the most
J. Clin. Lab. Anal.
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Fig. 2. Representative chromatogram of plasma group I patients (A)
and plasma group II patients (B).
commonly used drug in South America for the treatment
ofChagas diseasemainly due to availability issues (6). Un-
fortunately, little information is available on the pharma-
cokinetics of BNZ and the knowledge on its metabolism
TABLE 2. Correlation Coefficients of Human Urine Curve
R value 0.9965
Adjusted-R squared 0.9883
Residual sum of squares 3.41682 × 108
Observations N = 30
ANOVA FN–2 = 2454.27904 Prob > FN–2 = 0
Coefficients Standard error
Intercept (b) 2096.22642 1083.85506
Slope (m) 2100.7084 42.4037
TABLE 4. Sample Results
N Range Mean SD
Plasma samples
Group I patients 7 0.60–6.21 2.81 2.35
Group II patients 7 <LOQ–7.47 4.49 2.81
Group III patients 7 0.82–4.94 3.17 1.68
Urine samples 2 9.7–25.2 – –
and the identity of the main metabolites is very scarce,
and was not obtained in human beings. This situation is
significantly worse in the case of children and it is also
complicated by the fact that appropriate pediatric formu-
lations are not available. Actually, administration of BNZ
to children often requires tablet fractionation (7) and pe-
diatric dosing is based on incomplete pharmacologic data
corresponding to adults patients (5).
BNZ has been determined in biological matrices by dif-
ferential pulse polarography (8),UVspectrometry (9), and
HPLC (10–16) methods. A DNA-electrochemical biosen-
sor method was proposed for the application in biologi-
cal matrices but was not validated (17). Only three of all
thesemethodswere applied to human samples in a clinical
context (8, 10, 14).
HPLC is a widely used methodology for drug analy-
sis and is the preferred method for BNZ quantization.
However, there are no standardized HPLC methods pro-
posed for routine use in human clinical studies, with only
one method published so far for analysis of adult human
plasma (14) and none for urine. In human samples, ma-
trix specificity is very important due to potential metabo-
lite interferences in the detection and quantization of the
drug.
Although it can be considered as a tedious procedure in
clinical chemistry, freeze-drying of plasma samples pro-
vides advantages in storage, transportation, deproteiniza-
tion, and drug extraction of samples. Moreover, it nei-
ther interfered with the detection of the drug, nor did
it lead to a decrease in sensitivity. It must be considered
that the chagasic patients are often far away from the
TABLE 3. Validation Parameters
Human plasma Human urine
Accuracy 6.3% 6.1%
Precision 3.4% 2.8%
Sensitivity 0.04 μg/ml 0.5 μg/ml
LOD 0.14 μg/ml 1.7 μg/ml
LOQ 0.32 μg/ml 5.2 μg/ml
Linear range 0.30–20.00 μg/ml 5.0–45.0 μg/ml
Selectivity without metabolite interferences
Preanalysis handled time 20 min 15 min
Analytical instrumental time 9 min 7 min
Eco-compatibility without chlorated or cancerigen solvents; minimum organic solvents use
J. Clin. Lab. Anal.
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analytical laboratories, even in rural areas. The freeze-
dried samples better preserved during the transport for
long distances or storage for long times. Freeze-dryer
equipment can be found in some sanitary facilities. A
simple liquid–liquid extraction of plasma samples could
be applicable, but it would not present any advantage for
transportation, storage, and drug extraction in compari-
son with the described method.
On the preanalytical procedure, the evaporation of the
solvent was carried out under a stream of nitrogen, with-
out significant analytical differences with the use of a ro-
toevaporator. Thus, due to the high performance it had,
this technical procedure was carried out in our laboratory
using a rotary evaporator.
In our measurements, all real human plasma samples
values were within the linear range. The values ranged
from 0.20 μg/ml to 15.80 μg/ml, similar to previously
reported data (18). The values of validation parame-
ters justify the use of calibration curve with external
calibration.
There is an interest on the determination of clinically
significant plasma BNZ concentrations. To our knowl-
edge, there are two different scenarios: adult plasma con-
centrations and pediatric plasma concentrations. Based
on in vitro data and on pharmacokinetic adult human
studies, a therapeutic range between 3 and 6 μg/ml in
adult plasma samples was originally proposed. However,
lower values were observed in pediatric patients (19). The
LOQ of the method here described, 0.32 μg/ml, seems
to be appropriate in both contexts. In this work, most of
the pediatric samples normally obtained were of 2 ml of
plasma. It is important to note that minor sample vol-
umes would result in higher LOQ values. Nevertheless,
with this methodology, we could also have been working
with lower amount of sample, being still suitable in pe-
diatric context. Finally, it has been reported that higher
BNZ plasma concentrations are associated with higher
risk of toxicity (20, 21) but toxicity risks are low in pedi-
atric populations (7). The higher linear limit of our plasma
sample method is adequate for patient evaluation in both
clinical contexts.
The use of wavelengths between 313 nm and 324 nm is
described in the literature for detection of BNZbyHPLC-
UV in biological samples. In our experience, detection at
313 nmwavelength offered the best sensitivitywithout any
significant noise increase. LOD and LOQ of our method
are among the lowest reported in the literature and we
postulate that this is possibly the technical limit for any
HPLC analysis with UV detection.
The second chromatographic peak observed in many
specimens of a subgroup of plasma samples, had lower
retention times and similar UV absorption characteris-
tics as BNZ peak. The analysis of BNZ in these samples
using a direct spectrophotometric UV method without
chromatographic resolution (9) could be notoriously in-
terfered with this second substance. This peak also shows
similar chromatographic features to the findings of a pre-
vious work using mice as model (11), in which this signal
is assigned to the aminoderivative metabolite of BNZ. In
this study, the metabolite was detected in plasma sam-
ples taken three hours after the administration of BNZ.
Glioxal, another proposed BNZ metabolite (22), is not
compatible with this feature. In this sense, our method
bears similarities to the method described by Walton and
coworkers, being plausible that this signal corresponds
to a nitroreduced BNZ or similar metabolite with ben-
zyl chromophore. If this would be the case, it suggests
that our methodology could be used to detect and mea-
sure it. The results here obtained also indicate that it is
unlikely that the peak assigned to BNZ has any interfer-
ence from BNZ metabolites. At this time, there are no re-
ports for plasmatic metabolites identity of BNZ in human
beings.
In order to determine the clinical relevant concentra-
tions range in urine samples, previous studies of urinary
excretion of BNZ were analyzed. They showed that a mi-
nor portion of the parent drug is excreted in urine within
four days after an oral dose (8), but these data have never
been confirmed by other authors. Our 24-hour urine sam-
ples showed 9.7 μg/ml and 25.2 μg/ml values, reflecting
∼3% and ∼7% of BNZ of the oral doses. For this ma-
trix, the values of validation parameters justify the use of
calibration curve with external calibration.
CONCLUSIONS
We developed HPLC methods for the quantization of
BNZ in human plasma and urine. The methods described
are specific, accurate, precise, and sufficiently sensitive
for the quantization of BNZ in these matrices. Samples
preparation involves simple steps and the methods are
sufficiently fast. These methodologies showed to be suit-
able for the analysis of human urine and plasma samples
collected during pediatric clinical studies.
Supporting this main aspect, the described plasma
dosage technique is currently being used for the mea-
surement of BNZ in clinical samples of pediatric patients
treated for Chagas disease in a clinical trial (registry:
clinicaltrials.gov # NCT00699387).
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